Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SL
Sol-Gel Technologies Ltd. Ordinary Shares
SLGL
Mkt Cap
$210.0M
Volume
69.45K
Next Earnings
November 19th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SL
SLGL
SL
Sol-Gel Technologies Ltd. Ordinary Shares
SLGL
News
·
New Strong Buy Stocks for October 16th
Mkt Cap
$210.4M
Volume
69.44K
Next Earnings
November 19th
Chart
Financials
Earnings
News
About
Insider
Filings
New Strong Buy Stocks for October 16th
Zacks has added five stocks to its Strong Buy list based on increasing consensus earnings estimates over the last 60 days. The stocks span energy, technology distribution, immuno-oncology, biopharmaceutical, and chemical manufacturing sectors, with earnings estimate increases ranging from 3.5% to 30.6%.
Zacks Investment Research · Oct 16, 2026
SolGel Technologies (SLGL) Upgraded to Buy: Here's Why
Sol-Gel Technologies Ltd. (SLGL) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's Zacks Consensus Estimate has increased 41.9% over the past three months, positioning it in the top 20% of Zacks-covered stocks for estimate revisions. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation.
Zacks Investment Research · Oct 8, 2026
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) announced the pricing of an underwritten offering of 459,112 ordinary shares at $72.00 per share, generating approximately $33.1 million in gross proceeds. The offering, expected to close on March 25, 2026, includes participation from multiple institutional investors. Net proceeds will fund continued development of SGT-610, a Phase 3 topical hedgehog inhibitor for basal cell carcinoma prevention in Gorlin syndrome patients, along with working capital and general corporate purposes.
GlobeNewswire Inc. · Mar 24, 2026
Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Over 22 pharmaceutical companies are developing new drugs for basal cell neoplasms, with promising therapies targeting various molecular pathways and showing potential in clinical trials.
GlobeNewswire Inc. · Sep 10, 2025
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel Technologies completed patient enrollment for Phase-3 clinical trial of SGT-610 for Gorlin Syndrome, sold U.S. rights to EPSOLAY and TWYNEO to Mayne Pharma for $16 million, and reported a net income of $11.6 million in Q2 2025.
GlobeNewswire Inc. · Aug 15, 2025
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Technologies reported financial results for Q2 2024, including a net income of $1.9 million. The company provided updates on its pipeline, including the ongoing Phase 3 trial for SGT-610 in Gorlin Syndrome and the proof-of-concept study for SGT-210 in Darier disease. Sol-Gel also announced licensing agreements for its approved products TWYNEO and EPSOLAY in Europe and South Africa.
GlobeNewswire Inc. · Aug 16, 2024
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 20, 2024
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire Inc. · May 20, 2024
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
GlobeNewswire Inc. · May 16, 2024
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 9.09% and 7.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 14, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
SL
SLGL
Sol-Gel Technologies Ltd. Ordinary Shares
Buy
Sell
Market
Limit
Soon
SLGL
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any SLGL yet.
Related Tickers
DR
DRCT
—
TR
TRAW
—
Earnings